Advanced Neuromodulation Systems, Inc. (ANS), the company sponsoring the BROADEN clinical study, is a technology leader in implantable neurostimulation therapies, with nearly 30 years of experience, numerous technological firsts, multiple awards for excellence in product design and business, and more than 35,000 patients in over 35 countries with ANS devices used for chronic pain management. ANS’ goal is to improve the lives of the millions of people around the world who suffer with disabling pain or nervous system disorders. To learn more about ANS, visit www.ans-medical.com.

In 2005, ANS became a St. Jude Medical company. St. Jude Medical is a leading manufacturer of cardiac pacemakers, implantable defibrillators, and heart valves. Over one million mothers, fathers, grandparents, and children worldwide have received a life-saving St. Jude Medical device. To learn more about St. Jude Medical, visit www.sjm.com.